Axatilimab + Decitabine/Venetoclax for Acute Myeloid Leukemia
What You Need to Know Before You Apply
What is the purpose of this trial?
Axatilimab combined with Decitabine/Venetoclax for the treatment of TP53-mutated/deleted AML patients
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Induction Chemotherapy
Participants receive induction chemotherapy with decitabine and venetoclax to achieve MRD-negative complete remission
Consolidation
Participants undergo consolidation therapy with regular bone marrow biopsies every 3 months
Follow-up
Participants are monitored for safety, overall survival, and progression-free survival
What Are the Treatments Tested in This Trial?
Interventions
- Axatilimab
- Decitabine
- Venetoclax
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northside Hospital, Inc.
Lead Sponsor
Incyte Corporation
Industry Sponsor
Steven Stein
Incyte Corporation
Chief Medical Officer since 2015
MD from University of Witwatersrand
Hervé Hoppenot
Incyte Corporation
Chief Executive Officer since 2014
MBA from ESSEC Business School
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.